The Translational Genomics Research Institute (TGen), part of City of Hope, today announced that industry veteran Kevin Campbell has been appointed the Institute’s Chief Information Officer.
Campbell will oversee the design, development, and implementation of infrastructure systems, software applications, and IT support. He’ll also work to identify emerging technologies to be adopted by TGen that support the research and business objectives of the institute.
“I am pleased to welcome Kevin as our next CIO,” said Jeffrey Trent, Ph.D., TGen President and Research Director. “His knowledge of TGen and his extensive experience working with our faculty provides a seamless transition in the area of information technology and the application of high-performance computing to our life-sciences and precision medicine objectives.”
Campbell joined TGen in 2003, where he worked closely with the TGen faculty and scientific community to enable and accelerate research and discovery. He was a key driver of the team that designed and built two supercomputer systems for TGen that have placed in the top 100 most powerful supercomputers in the world.
Additionally, he played a primary role in incubating numerous startups developed at TGen, most recently overseeing IT operations at Ashion Analytics LLC, which Exact Sciences Corp. acquired in February 2021.
“I’m honored to be named CIO and look forward to leading TGen’s digital efforts by identifying and implementing the latest tools and applications in support of TGen’s faculty, whose patient-focused work continues to push the boundaries of precision medicine,” said Campbell.
An industry veteran with over 30 years’ experience, Campbell has held numerous IT and technology related positions in metropolitan Phoenix designing, deploying and managing large-scale systems to solve complex problems.
Campbell succeeds James Lowey, who now leads the TGen spin-out Kaligent, which provides software products and services designed to help healthcare and life science customers derive data-driven insights that impact patient care and outcomes.
About TGen, part of City of Hope
Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based nonprofit organization dedicated to conducting groundbreaking research with life-changing results. TGen is part of City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases. This precision medicine affiliation enables both institutes to complement each other in research and patient care, with City of Hope providing a significant clinical setting to advance scientific discoveries made by TGen. TGen is focused on helping patients with neurological disorders, cancer, diabetes and infectious diseases through cutting-edge translational research (the process of rapidly moving research toward patient benefit). TGen physicians and scientists work to unravel the genetic components of both common and complex rare diseases in adults and children. Working with collaborators in the scientific and medical communities worldwide, TGen makes a substantial contribution to help patients through efficiency and effectiveness of the translational process.